AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chuna
Description: Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
Study NCT02968836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin only
Description: The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacoacupuncture
Description: This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacoacupuncture
Description: This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
Study NCT04660175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean herbal medicine
Description: Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
Study NCT04660175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean herbal medicine
Description: Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
Study NCT03234647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doraya catheter
Description: Temporary deployment of the Doraya catheter in AHF patients.
Study NCT03292003 — intervention group
Intervention type: DEVICE
Intervention: Journey II BCS Total Knee System
Study NCT02887157 — intervention group
Intervention type: DEVICE
Intervention: Swept Source OCT
Description: The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
Study NCT04420910 — intervention group
Intervention type: OTHER
Intervention: Balance
Description: To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
Study NCT04420910 — intervention group
Intervention type: OTHER
Intervention: Lower Limb Strength
Description: A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
Study NCT04420910 — intervention group
Intervention type: OTHER
Intervention: Functional mobility
Description: The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
Study NCT02634450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alere q
Study NCT02467166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circa™ Probe
Description: The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
Study NCT04218266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.
Study NCT03337425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational group therapy
Description: The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
Study NCT03337425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Waiting list and standard treatment (ADHD treatment as usual)
Study NCT03337425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
Study NCT03337425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
Study NCT02204033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc - labelled hMAb BIWA 4
Study NCT02204033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 186 Re - labelled hMAb BIWA 4
Study NCT02204033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unlabelled hMAb BIWA 4 - low dose
Study NCT02204033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unlabelled hMAb BIWA 4 - medium dose
Study NCT02204033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unlabelled hMAb BIWA 4 - high dose
Study NCT03689881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomosynthesis of SI joints
Description: All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction.
Study NCT02758613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT02758613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04454580 — intervention group
Intervention type: DRUG
Intervention: Venetoclax
Description: treatment with azacitidine or decitabine in combination with venetoclax
Study NCT03310580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study NCT03310580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.04%
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study NCT03310580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-13324 Ophthalmic Solution Placebo
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study NCT01548794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: To receive 2 ml heavy bupivacaine + 0,6 ml saline
Study NCT01548794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
Study NCT01548794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration anesthesia
Description: To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
Study NCT04991064 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Complete denture base modified by Titanium dioxide nanoparticles.
Description: Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
Study NCT04218266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Capsule, taken orally twice a day.
Study NCT04218266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BAY2433334 matching placebo
Description: Tablet, taken orally once a day.
Study NCT04218266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apixaban matching placebo
Description: Capsule, taken orally twice a day.
Study NCT01577225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPSITE POST-OP VISIBLE
Description: Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
Study NCT01577225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tape and Gauze
Description: Patient will be treated with tape and gauze up to 14 days post surgery
Study NCT03628235 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
Study NCT03435666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study NCT03435666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study NCT03435666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELODA
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study NCT00927719 — intervention group
Intervention type: BIOLOGICAL
Intervention: ACAM2000® smallpox vaccine
Description: Previous vaccination, no vaccine is administered in this study.
Study NCT01854671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family planning counseling let by community health workers
Description: The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
Study NCT04203875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orencia® (Abatacept)
Description: Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
Study NCT01557738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Trial
Description: The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
Study NCT01303458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Needs Surveillance (BNS) protocol
Description: The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
Study NCT02640118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide
Description: single injection of 20 µg lixisenatide subcutaneously
Study NCT02640118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lixisenatide-Placebo
Study NCT01557738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Flavanol Trial
Description: The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
Study NCT01557738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Trial; long-term
Description: The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
Study NCT02887157 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
Study NCT02887157 — intervention group
Intervention type: OTHER
Intervention: Scavenged blood collection
Description: Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
Study NCT04356300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosome of MSC
Description: Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
Study NCT01679938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: primary obesity prevention
Description: 1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention.
Study NCT01009905 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
Study NCT02872597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium
Study NCT02872597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Study NCT02872597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: albuterol prescribed by the clinical team per our PICU's Asthma Carepath
Study NCT02872597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: albuterol prescribed by the clinical team per our PICU's Asthma Carepath
Study NCT02872597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
Study NCT02872597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
Study NCT02640118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized liquid meal
Description: standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Study NCT02640118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standardized liquid meal
Description: standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Study NCT04512001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11456
Description: Participants will receive MSB11456 subcutaneously, once a week.
Study NCT04512001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra
Description: Participants will receive EU-approved RoActemra® subcutaneously, once a week.
Study NCT03070028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: platelet rich plasma will be applied to sinus cavity
Study NCT02759783 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
Study NCT02759783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
Study NCT03466398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivify Health RPM Protocol
Description: The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
Study NCT02759783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
Study NCT01557738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Flavanol Trial; long-term effects
Description: The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
Study NCT05326321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
Study NCT01435369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
Study NCT03512132 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
Study NCT01005641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg daily
Study NCT01005641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: taken orally, daily, at dose recommended after dose finding part of study
Study NCT01489709 — intervention group
Intervention type: DRUG
Intervention: Vesicare
Description: oral